Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGNNASDAQ:NXLNASDAQ:PYPDNASDAQ:STRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.12-4.1%$2.77$2.00▼$6.75$24.29M1.3211,249 shs13,007 shsNXLNexalin Technology$1.82$2.05$0.53▼$4.49$24.26M4.61.24 million shs21,643 shsPYPDPolyPid$2.85+8.8%$2.77$2.30▼$5.09$29.04M1.2814,610 shs70,408 shsSTRRStar Equity$2.16+8.0%$2.16$1.72▼$5.35$6.44M0.6713,800 shs61,610 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+2.14%+3.15%-10.20%-39.01%-61.64%NXLNexalin Technology0.00%+4.60%-4.71%-30.00%+17.42%PYPDPolyPid+3.97%-2.93%-4.38%-12.08%-45.10%STRRStar Equity-1.00%+14.40%-17.07%-2.38%-55.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies2.415 of 5 stars3.73.00.00.01.90.01.3NXLNexalin Technology2.5032 of 5 stars3.53.00.00.01.93.30.0PYPDPolyPid2.1486 of 5 stars3.63.00.00.01.91.70.0STRRStar Equity2.1243 of 5 stars0.05.00.00.03.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$12.50489.62% UpsideNXLNexalin Technology 3.00Buy$5.00174.73% UpsidePYPDPolyPid 3.25Buy$11.33297.66% UpsideSTRRStar Equity 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STRR, CLGN, PYPD, and NXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/27/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/24/2025NXLNexalin TechnologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$5.002/12/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/4/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$515K47.15N/AN/A$2.47 per share0.86NXLNexalin Technology$168.72K143.77N/AN/A$0.43 per share4.23PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ASTRRStar Equity$53.36M0.13$0.35 per share6.11$14.63 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$7.02M-$1.46N/AN/AN/A-2,680.00%-77.05%-61.43%5/27/2025 (Estimated)NXLNexalin Technology-$4.65M-$0.82N/A∞N/A-3,407.98%-187.59%-167.21%5/9/2025 (Estimated)PYPDPolyPid-$29.02M-$4.97N/A∞N/AN/A-624.10%-129.28%5/6/2025 (Estimated)STRRStar Equity$25.13M-$3.91N/AN/AN/A-12.41%-8.72%-4.62%5/19/2025 (Estimated)Latest STRR, CLGN, PYPD, and NXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025STRRStar Equity-$0.25N/AN/AN/A$16.35 millionN/A5/14/2025Q1 2025PYPDPolyPid-$0.74N/AN/AN/AN/AN/A3/26/2025Q4 2024CLGNCollPlant Biotechnologies-$0.42-$0.34+$0.08-$0.34$0.36 million$0.17 million3/20/2025Q4 2024STRRStar Equity-$0.17$0.15+$0.32-$0.94$14.00 million$17.10 million3/14/2025Q4 2024NXLNexalin TechnologyN/A-$0.28N/A-$0.28N/A$0.03 million2/12/2025Q4 2024PYPDPolyPid-$0.90-$1.13-$0.23-$1.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A5.385.23NXLNexalin TechnologyN/A16.4215.89PYPDPolyPid0.081.311.00STRRStar Equity0.212.051.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%NXLNexalin Technology0.65%PYPDPolyPid26.47%STRRStar Equity3.84%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%NXLNexalin Technology24.00%PYPDPolyPid24.70%STRRStar Equity33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7011.46 million10.36 millionOptionableNXLNexalin Technology313.33 million10.11 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataSTRRStar Equity4603.22 million2.14 millionNot OptionableSTRR, CLGN, PYPD, and NXL HeadlinesRecent News About These CompaniesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Procaps Group (OtherPROCF) and Star Equity Holdings (STRR)March 26, 2025 | markets.businessinsider.comStar Equity Holdings, Inc. (NASDAQ:STRR) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comStar Equity Holdings Reports Mixed Q4 Earnings ResultsMarch 21, 2025 | tipranks.comStar Equity reports Q4 EPS 15c vs (10c) last yearMarch 21, 2025 | markets.businessinsider.comStar Equity Holdings, Inc. (STRR) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comStar Equity (STRR) Q4 Earnings and Revenues Top EstimatesMarch 20, 2025 | zacks.comStar Equity Holdings, Inc. Announces 2024 Fourth Quarter and Full Year Financial ResultsMarch 20, 2025 | gurufocus.comStar Equity Holdings, Inc. Announces 2024 Fourth Quarter and Full Year Financial ResultsMarch 20, 2025 | globenewswire.comStar Equity Holdings, Inc. to Announce Fourth Quarter 2024 Financial Results on March 20, 2025March 13, 2025 | quiverquant.comStar Equity Holdings to Release Fourth Quarter 2024 Financial Results on March 20thMarch 13, 2025 | globenewswire.comStar Equity Holdings announces executive bonuses and targetsMarch 13, 2025 | uk.investing.comKey deals this week: Walgreens Boots, Honeywell, Amex and moreMarch 8, 2025 | msn.comStar Equity Holdings Acquires Alliance Drilling ToolsMarch 4, 2025 | tipranks.comStar Equity Holdings, Inc.: Star Equity Holdings Acquires Alliance Drilling ToolsMarch 4, 2025 | finanznachrichten.deStar Equity’s KBS Builders wins two large commercial contractsMarch 4, 2025 | markets.businessinsider.comStar Equity acquires Alliance Drilling ToolsMarch 4, 2025 | markets.businessinsider.comKBS Builders Wins Two Large Commercial Contracts Totaling $5.2 Million for Multifamily Construction Projects in MaineMarch 4, 2025 | globenewswire.comStar Equity Holdings Acquires Alliance Drilling ToolsMarch 4, 2025 | globenewswire.comStar Equity subsidiary signs $3.2M contract for construction project in MaineJanuary 7, 2025 | markets.businessinsider.comStar Equity Holdings, Inc. Subsidiary KBS Builders Secures $3.2 Million Contract for Multifamily Housing Project in MaineJanuary 7, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTRR, CLGN, PYPD, and NXL Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$2.12 -0.09 (-4.07%) As of 03:59 PM EasternCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Nexalin Technology NASDAQ:NXL$1.82 0.00 (0.00%) As of 04:00 PM EasternNexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.PolyPid NASDAQ:PYPD$2.85 +0.23 (+8.78%) As of 03:56 PM EasternPolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Star Equity NASDAQ:STRR$2.16 +0.16 (+8.00%) As of 04:00 PM EasternStar Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
